Fewer wet wipes
Wet wipe use fell from 196 to 5 units per week by Week 3 in a 21-day Australian home care pilot.
Healthcare Administrators & Facility Leadership
Carebidet is an automated in-bed toileting system for appropriate bedbound individuals or those requiring significant assistance. For administrators, the question is broader than the technology: can it improve workflow, support staff, reduce recurring care burden and deliver measurable value in your facility?
Observed Carebidet Results
Early Australian pilots reported meaningful reductions in caregiver time, consumables and manual handling. These limited observational findings are not guarantees of what every facility will experience, but they identify practical measures to test in a structured facility trial.
Wet wipe use fell from 196 to 5 units per week by Week 3 in a 21-day Australian home care pilot.
Glove use fell from 91 to 4 pairs per week in the same pilot.
Use fell from 52 per week at baseline to zero by Week 3.
Across 115 automated cycles, the pilot recorded 986 minutes of caregiver time saved over 21 days.
Direct Economic Signal
The report calculated an average weekly saving of AUD $987.80, driven primarily by caregiver time recovery and reduced disposable pad and linen use. The study involved one fully bedbound participant and should be viewed as hypothesis-generating rather than as a facility-wide forecast.
Published Clinical Research
A 2021 quasi-experimental ICU study compared Carebidet-assisted defecation care with standard wet-wipe cleansing in 55 critical care patients. The findings do not prove that Carebidet prevents pressure injuries, but they provide published clinical evidence related to incontinence-associated dermatitis and pressure injury risk.
The study reported significant group-by-time effects for incontinence-associated dermatitis and Braden pressure injury risk scores. The authors concluded that Carebidet-assisted care was associated with slower IAD progression and preserved skin integrity relative to standard manual care during the seven-day observation period.
What this means: The study supports further evaluation of Carebidet’s potential skin-related benefits, but it should not be interpreted as proof that Carebidet prevents hospital-acquired pressure injuries.
A 2026 peer-reviewed study found positive service adequacy scores for core functional attributes including effectiveness, convenience and safety after four weeks of use.
View DOI →A 2026 discrete choice study found strong preferences for combined urine/feces detection, automatic waste disposal, and washing and drying after defecation.
View DOI →Why the Evidence May Matter
The strongest current value proposition is not a promise of a specific outcome. It is a measurable change in how toileting and hygiene care are delivered, supported by published evidence that can help facilities evaluate whether those changes translate into better operational or clinical results.
Observed pilot results are presented as observed results. Peer-reviewed research is identified as research. Potential benefits are described as potential benefits. Carebidet is not represented here as proven to prevent pressure injuries, UTIs, mortality, litigation or reimbursement penalties.
Facility Impact Calculator
The published pilots give us variables worth measuring: caregiver time, wipes, gloves, pads / linens, handling and other recurring care costs. Use your own assumptions here rather than applying the Australian results directly to your facility.
This is an operational planning model, not a clinical outcome guarantee. Equipment acquisition, service, training and facility specific implementation costs should be added separately.
Measure It in Your Facility
A controlled trial can determine whether Carebidet fits the population, staffing model and operating environment while generating the facility-specific data needed for an informed decision.
Facility Evaluation
We can help identify appropriate users, baseline measures, and a focused evaluation plan.